Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Vulvovaginal Candidiasis-Pipeline Review, H1 2015

Vulvovaginal Candidiasis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Vulvovaginal Candidiasis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vulvovaginal Candidiasis-Pipeline Review, H1 2015', provides an overview of the Vulvovaginal Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vulvovaginal Candidiasis Overview 6

Therapeutics Development 7

Pipeline Products for Vulvovaginal Candidiasis-Overview 7

Pipeline Products for Vulvovaginal Candidiasis-Comparative Analysis 8

Vulvovaginal Candidiasis-Therapeutics under Development by Companies 9

Vulvovaginal Candidiasis-Pipeline Products Glance 10

Clinical Stage Products 10

Vulvovaginal Candidiasis-Products under Development by Companies 11

Vulvovaginal Candidiasis-Companies Involved in Therapeutics Development 12

Actavis plc 12

Grupo Ferrer Internacional, S.A. 13

NovaDigm Therapeutics, Inc. 14

Viamet Pharmaceuticals, Inc. 15

Vulvovaginal Candidiasis-Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

albaconazole-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

arasertaconazole-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

NDV-3-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

NDV-3A-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

PEV-7-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

VT-1161-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Vulvovaginal Candidiasis-Recent Pipeline Updates 34

Vulvovaginal Candidiasis-Dormant Projects 38

Vulvovaginal Candidiasis-Discontinued Products 39

Vulvovaginal Candidiasis-Product Development Milestones 40

Featured News & Press Releases 40

Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 40

Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 40

Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 41

Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 42

Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 42

Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis 43

Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees 44

Oct 11, 2011: Pevion's Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity 45

Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine 45

Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for Vulvovaginal Candidiasis, H1 2015 7

Number of Products under Development for Vulvovaginal Candidiasis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Products under Development by Companies, H1 2015 11

Vulvovaginal Candidiasis-Pipeline by Actavis plc, H1 2015 12

Vulvovaginal Candidiasis-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 13

Vulvovaginal Candidiasis-Pipeline by NovaDigm Therapeutics, Inc., H1 2015 14

Vulvovaginal Candidiasis-Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 15

Assessment by Monotherapy Products, H1 2015 16

Number of Products by Stage and Target, H1 2015 18

Number of Products by Stage and Mechanism of Action, H1 2015 20

Number of Products by Stage and Route of Administration, H1 2015 22

Number of Products by Stage and Molecule Type, H1 2015 24

Vulvovaginal Candidiasis Therapeutics-Recent Pipeline Updates, H1 2015 34

Vulvovaginal Candidiasis-Dormant Projects, H1 2015 38

Vulvovaginal Candidiasis-Discontinued Products, H1 2015 39

List of Figures

Number of Products under Development for Vulvovaginal Candidiasis, H1 2015 7

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Assessment by Monotherapy Products, H1 2015 16

Number of Products by Top 10 Targets, H1 2015 17

Number of Products by Stage and Top 10 Targets, H1 2015 18

Number of Products by Top 10 Mechanism of Actions, H1 2015 19

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 20

Number of Products by Top 10 Routes of Administration, H1 2015 21

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22

Number of Products by Top 10 Molecule Types, H1 2015 23

Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

Grupo Ferrer Internacional, S.A.

NovaDigm Therapeutics, Inc.

Viamet Pharmaceuticals, Inc.

Vulvovaginal Candidiasis Therapeutic Products under Development, Key Players in Vulvovaginal Candidiasis Therapeutics, Vulvovaginal Candidiasis Pipeline Overview, Vulvovaginal Candidiasis Pipeline, Vulvovaginal Candidiasis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com